MS Trial Alert: Investigators Nationwide Recruiting People with All Types of MS for Early, Phase I Study to Determine Safety of Experimental Antibody
May 22, 2013
Summary: Investigators nationwide are recruiting 60 people with all types of MS for a phase I study to determine the safety and tolerability of rHIgM22, an experimental antibody. The study is funded by Acorda Therapeutics, Inc.
Apr 22, 2013
Summary: Researchers at the National Institutes of Health in Bethesda, Maryland are looking to recruit 80 people with Primary-Progressive Multiple Sclerosis to evaluate the safety and effectiveness of Idebenone, an oral experimental drug. The study is funded by the National Institute of Neurological Disorders and Stroke.
Apr 15, 2013
Summary: Researchers at the National Institutes of Health in Bethesda, Maryland are looking to recruit 80 people with secondary-progressive Multiple Sclerosis (secondary-progressive MS) to evaluate the safety and effectiveness of rituximab. Rituximab is an experimental drug for treating MS. In this study it will be given intravenously and directly into the cerebrospinal fluid by lumbar puncture (“spinal tap”). The study is funded by the National Institute of Neurological Disorders and Stroke.
MS Trial Alert: Investigators Recruiting People with MS for Study of New Investigational Dosage of Approved Medication for Urinary Incontinence
Dec 17, 2012
Investigators at sites worldwide are recruiting 184 people for a study of a new investigational dosage of an approved medication, which is injected into the bladder muscle to treat urinary incontinence in people with MS. The study is sponsored by Allergan, Inc.
MS Trial Alert: Investigators Recruiting for Personalized T Cell Immunotherapy Study in Secondary-Progressive MS
Oct 22, 2012
Investigators in the United States and Canada are recruiting 180 people with secondary-progressive MS for a study to determine the effectiveness of TcelnaTM (imilecleucel-T, Opexa Therapeutics) in slowing disease progression in this progressive population. Tcelna is an experimental T-cell treatment made with a person’s own immune cells (autologous T-cell immunotherapy) administered subcutaneously (under the skin). The study, also known as the Abili-T study, is sponsored by Opexa Therapeutics, Inc.
Aug 24, 2012
Summary: U.S. investigators are recruiting 300 people with early relapsing-remitting MS to detect factors that might help better predict which patients do better on natalizumab (Tysabri®, Biogen Idec and Elan) in this population. This is an observational study: The investigators are observing people who have been diagnosed with relapsing-remitting MS within the past three years, and have decided to take Tysabri – no study drug will be provided. The study, also known as the STRIVE study, is sponsored by Biogen Idec.
Apr 19, 2012
Investigators at several centers nationwide are recruiting 172 people with relapsing-remitting MS to compare the effectiveness of the current recommended amount of vitamin D supplementation versus high dose vitamin D supplementation at reducing MS disease activity, when added to standard therapy with glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries). The principal investigator is Ellen Mowry, MD, MCR (Johns Hopkins University, Baltimore) and the study is funded by a research grant from the National MS Society.
Apr 02, 2012
Summary: Investigators worldwide are recruiting 100 people with relapsing-remitting MS for a study testing the use of a prefilled syringe to administer monthly under the skin injections of the experimental therapy daclizumab high yield process (DAC HYP). Specifically, the study is looking at the immune response that is stimulated by this delivery method, and how the drug is absorbed in the body. This study – also called the OBSERVE study – is being sponsored by Biogen Idec and Abbott Biotherapeutics.
Feb 07, 2012
Summary: Investigators nationwide are recruiting 400 people with secondary-progressive MS or relapsing-remitting MS to compare the effectiveness of three doses of the oral drug AVP-923 (Nuedexta®, dextromethorphan hydrobromide and quinidine sulfate, Avanir Pharmaceuticals) or inactive placebo in reducing central neuropathic pain. The study is funded by Avanir Pharmaceuticals.
MS Trial Alert: Investigators Recruiting for Studies Comparing Ocrelizumab to Rebif® in People with Relapsing MS
Jan 17, 2012
Summary: Investigators worldwide are recruiting a total of 1600 people with relapsing MS (http://www.nationalmssociety.org/about-multiple-sclerosis/relapsing-ms/index.aspx) for two phase III studies comparing the effectiveness of intravenous ocrelizumab (Genentech) versus Rebif® (interferon beta-1a, EMD Serono & Pfizer). Ocrelizumab, an experimental therapy, is also being tested in primary-progressive MS (http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=5797). The study is funded by F. Hoffmann-La Roche Ltd.
Dec 19, 2011
Summary: Investigators worldwide are recruiting 630 people with primary-progressive MS (http://www.nationalmssociety.org/about-multiple-sclerosis/progressive-ms/primary-progressive-ms/index.aspx) to study the effectiveness of intravenous ocrelizumab (Genentech) versus inactive placebo. This experimental therapy is also being tested in relapsing MS. The study is funded by F. Hoffmann-La Roche Ltd.
Update: Ohio Stem Cell Study Recruiting People with MS -- Study supported by the CDMRP, thanks in large part to MS activists who helped secure funding
Aug 23, 2011
Summary: Investigators in Ohio are recruiting 24 people for first study in U.S. of the safety of transplanting one’s own mesenchymal stem cells (derived from bone marrow) in relapsing forms of MS.
Aug 23, 2011
Summary: Investigators worldwide are recruiting over 800 people with secondary-progressive MS (http://www.nationalmssociety.org/about-multiple-sclerosis/relapsing-ms/secondary-progressive-ms-spms/index.aspx) to determine the effectiveness of natalizumab (Tysabri®, Biogen Idec and Elan) at reducing the progression of disability in this population. The study, also known as the ASCEND study, is sponsored by Biogen Idec.
Early Clinical Trial Results and Observational Study Support Further Research of “Probiotic” Parasitic Worm Treatment Approach in MS
Mar 18, 2011
Two recently published studies are reporting results related to parasitic worms, called helminths, and their possible implications for treating multiple sclerosis. Further study, including the second phase of the reported clinical trial supported by the National MS Society, should determine whether a “probiotic” treatment approach using relatively harmless parasitic worms to alter immune activity will benefit people with MS.
Mar 18, 2011
Summary: Investigators are conducting a trial to test the safety and effectiveness of abatacept, an experimental drug administered intravenously, in 123 people with relapsing-remitting MS, versus inactive placebo. The trial also is known as the ACCLAIM trial, and is being conducted by the Immune Tolerance Network and sponsored by the National Institute for Allergy and Infectious Disease.
Aug 13, 2010
Summary: Investigators at the University of Alabama at Birmingham are recruiting 66 people with relapsing-remitting, secondary-progressive, or primary-progressive MS to participate in a study comparing the effectiveness of two types of physical therapy for increasing movement (improving nonuse) of the arm in MS.
MS Trial Alert: Investigators in Buffalo Recruiting for Research Study on Venous Insufficiency, or CCSVI, in People with MS and Others
Dec 22, 2009
Summary: Investigators at the University of Buffalo are recruiting 1600 adults and 100 children for a research study investigating the frequency of CCSVI (http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2206) in people with MS when compared to healthy controls and controls with other neurological disorders.
Exploring Why Physical Activity is Reduced in People with MS: Society-funded Investigators Seek Participants
Aug 19, 2008
Investigators funded by the National MS Society are seeking people with MS to participate in a study exploring whether the frequency and severity of MS-related symptoms influence physical activity.